Long-Term Safety with Sarilumab Plus Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) and Sarilumab Monotherapy in Rheumatoid Arthritis (RA): An Integrated Analysis with 9,000 Patient-Years (Pt-Yrs) of Follow-up

被引：0

作者：

Fleischmann, Roy ^{[1
]}

Lin, Yong ^{[2
]}

St John, Gregory ^{[3
]}

van der Heijcle, Desiree ^{[4
]}

Qiu, Chunfu ^{[2
]}

Jose Gomez-Reino, Juan ^{[5
]}

Maldonado-Cocco, Jose A. ^{[6
]}

Stanislav, Marina ^{[7
]}

Seriolo, Bruno ^{[8
]}

Burmester, Gerd R. ^{[9
]}

机构：

[1] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA

[2] Sanofi Genzyme, Bridgewater, NJ USA

[3] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA

[4] Leiden Univ, Med Ctr, Leiden, Netherlands

[5] Complejo Hosp Univ Santiago, IDIS, Santiago, Spain

[6] Buenos Aires Univ, Sch Med, Buenos Aires, DF, Argentina

[7] Res Rheumatol Inst, Moscow, Russia

[8] Univ Genoa, Dept Internal Med, Genoa, Italy

[9] Charite Univ Med Berlin, Berlin, Germany

来源：

ARTHRITIS & RHEUMATOLOGY | 2018年 / 70卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2527

引用

页数：3

共 7 条

[1] LONG-TERM SAFETY WITH SARILUMAB PLUS CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS AND SARILUMAB MONOTHERAPY IN RHEUMATOID ARTHRITIS: AN INTEGRATED ANALYSIS WITH 9,000 PATIENT-YEARS OF FOLLOW-UP
Fleischmann, Roy
Lin, Yong
St John, Gregory
van der Heijde, Desiree
Qiu, Chunfu
Carlos Gomez-Reino, Juan
Antonio Maldonado-Cocco, Jose
Stanislav, Marina
Seriolo, Bruno
Tranter, Lesley
Burmester, Gerd R.
[J]. RHEUMATOLOGY, 2019, 58
[2] LONG-TERM SAFETY WITH SARILUMAB PLUS CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS AND SARILUMAB MONOTHERAPY IN RHEUMATOID ARTHRITIS: AN INTEGRATED ANALYSIS WITH 9,000 PATIENT-YEARS OF FOLLOW-UP
Fleischmann, Roy
Lin, Yong
St John, Gregory
van der Heijde, Desiree
Qiu, Chunfu
Jose Gomez-Reino, Juan
Antonio Maldonado-Cocco, Jose
Stanislav, Marina
Seriolo, Bruno
Burmester, Gerd Ruediger
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1130 - 1131
[3] LONG-TERM TREATMENT WITH SARILUMAB PLUS CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (CSDMARDS): POOLED SAFETY AND EFFICACY WITH OVER 4 YEARS' TREATMENT
van Hoogstraten, Hubert
St John, Gregory
Thangavelu, Karthinathan
Jose Gomez-Reino, Juan
Antonio Maldonado-Cocco, Jose
Carlos Salazar, Juan
Huizinga, Thomas
Wilson, Elaine
Burmester, Gerd R.
[J]. RHEUMATOLOGY, 2019, 58 : 74 - 75
[4] Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up
Fleischmann, Roy
Genovese, Mark C.
Lin, Yong
St John, Gregory
van der Heijde, Desiree
Wang, Sheldon
Jose Gomez-Reino, Juan
Antonio Maldonado-Cocco, Jose
Stanislav, Marina
Kivitz, Alan J.
Burmester, Gerd R.
[J]. RHEUMATOLOGY, 2020, 59 (02) : 292 - 302
[5] Long-Term Treatment with Sarilumab Plus Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs): Pooled Safety and Efficacy with over 4 Years' Treatment
Genovese, Mark C.
van Hoogstraten, Hubert
St John, Gregory
Dong, Qunming
Jose Gomez-Reino, Juan
Maldonado-Cocco, Jose A.
Carlos Salazar, Juan
Huizinga, Tom W. J.
Burmester, Gerd R.
[J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
[6] Early Targeted Combination Treatment With Conventional Synthetic Disease-Modifying Antirheumatic Drugs and Long-Term Outcomes in Rheumatoid Arthritis: Ten-Year Follow-Up Results of a Randomized Clinical Trial
Rantalaiho, Vappu
Sandstrom, Tia
Koski, Juhani
Hannonen, Pekka
Mottonen, Timo
Kaipiainen-Seppanen, Oili
Yli-Kerttula, Timo
Kauppi, Markku J.
Uutela, Toini
Malmi, Timo
Julkunen, Heikki
Laasonen, Leena
Kautiainen, Hannu
Leirisalo-Repo, Marjatta
[J]. ARTHRITIS CARE & RESEARCH, 2019, 71 (11) : 1450 - 1458
[7] LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS FROM CHINA, BRAZIL, AND SOUTH KOREA WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS: RESULTS AT 64 WEEKS
Zeng, X.
Zhao, D.
Radominski, S.
Keiserman, M.
Lee, C. K.
Martin, N.
Meerwein, S.
Sui, Y.
Park, W.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1156 - 1157

← 1 →